Forest Laboratories
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Forest Laboratories sits in the top decile of US sponsors by registered trial count (#194 of 15,742 sponsors by registered trial count).
Forest Laboratories: 145 sponsored US clinical trials, none currently recruiting.
Forest Laboratories sponsors 145 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 127 completed. 100 of these trials are in Phase 3-4 (later-stage) and 43 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Major Depressive Disorder, with 9 trials.
Top-decile sponsor footprint
Forest Laboratories ranks in the top decile of sponsors by registered trial count (#194 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
127 of 145 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
145 total, page 3 of 3
Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections
NCT00633152
A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)
NCT00788593
Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia
NCT00621504
A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)
NCT00644358
Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea
NCT00559364
A Study of the Effect of Nebivolol to Evaluate Its Vasodilatory Effects in Hypertensive Patients
NCT00648895
Study to Evaluate Symptoms in Patients Treated With Nebivolol or Metoprolol Extended-release (ER) for Hypertension
NCT00547300
A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring
NCT00618956
Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)
NCT00513682
Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia
NCT00509106
Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute Mania
NCT00488618
Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections
NCT00423657
Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections
NCT00424190
Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia
NCT00404573
Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI)
NCT00408317
Fixed Dose Comparison of Escitalopram to an Active Comparator in Severely Depressed Patients
NCT00384436
Acamprosate Initiated During Alcohol Detoxification
NCT00360594
Efficacy and Safety of Itopride vs Placebo in Heartburn
NCT00382577
A Comparison Study of Apadenoson and Adenosine to Treadmill Exercise Stress.
NCT00380198
Study of Oglemilast for the Prevention of Asthma.
NCT00322283
The Safety and Efficacy of Dexloxiglumide for the Relief of Symptoms of Functional Dyspepsia.
NCT00303264
Study of Oglemilast for the Treatment of Asthma
NCT00322686
Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency
NCT00297167
Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency
NCT00981214
Study of Milnacipran for the Treatment of Fibromyalgia
NCT00314249
Effect of Azimilide Dihydrochloride on Renal Function
NCT00318838
Compassionate Use Study of 125 mg Per Day of Azimilide Dihydrochloride in One Patient
NCT00752596
Effects of Itopride on Gastric Motor and Sensory Functions in Healthy Volunteers
NCT00370110
Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease)
NCT00334906
A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging
NCT00162071
A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease
NCT00322153
Study of Desmoteplase (International Nonproprietary Name [INN]) in Acute Ischemic Stroke (DIAS-2)
NCT00111852
A Study to Examine MPI SPECT Imaging With BMS068645 and Adenosine Compared to Coronary Angiography
NCT00162084
Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder
NCT00109044
Study of Escitalopram in Adult Patients With Major Depressive Disorder
NCT00108979
The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder
NCT00107120
An Evaluation of the Safety and Efficacy of Memantine in Patients With Acute Mania Associated With Bipolar I Disorder
NCT00106405
Study of Milnacipran for the Treatment of Fibromyalgia
NCT00098124
An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's Disease
NCT00097916
Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients
NCT00097942
The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease
NCT00090116
Long Term Safety of 125 mg Per Day of Oral Azimilide in Patients With Implantable Cardioverter Defibrillator (ICDs)
NCT00751738
Efficacy and Safety Evaluation of Azimilide Dihydrochloride in Patients With Implantable Cardioverter Defibrillators
NCT00035490
Efficacy and Safety of Azimilide in the Prophylactic Treatment of Patients With Atrial Fibrillation.
NCT00035464
Efficacy and Safety of Azimilide for the Treatment of Patients With Atrial Fibrillation
NCT00035477
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 34 |
| Phase 3 | 75 |
| Phase 4 | 25 |
How the Forest Laboratories archive is shaped
145 indexed studies, none listed as recruiting (0% open); 127 completed (88%).
Phase mix: 100 late (III/IV) vs 43 early (I/II) (later-stage heavy).
Top condition: Major Depressive Disorder (9 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Forest Laboratories: archived-pipeline peers nationwide
Peers matched on 145 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Forest Laboratories sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 145 archived trials
- National Institute of Environmental Health Sciences (NIEHS) · 145 trials · 10% recruiting
- HealthPartners Institute · 146 trials · 8% recruiting
- Mylan Pharmaceuticals · 146 trials · 1% recruiting
- SCRI Development Innovations · 146 trials · 3% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Forest Laboratories page
145 registered trials is a research-attention snapshot, not an endorsement of Forest Laboratories or any single study.
- None of Forest Laboratories's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Major Depressive Disorder is the condition Forest Laboratories studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Major Depressive Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Forest Laboratories pipeline card: 145 registered trials from official public datasets.Report a data error.